Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
Candel Therapeutics appointed Mark Sims as Chief Commercial Officer, effective July 6, 2026, to lead the commercial strategy and launch readiness for aglatimagene besadenovec. The appointment supports the planned Biologics License Application submission in the fourth quarter of 2026 and a potential commercial launch in 2027 for intermediate- to high-risk localized prostate cancer. Mr.
Key figures
- Potential launch year
- 2027
- Bla submission timeline
- Q4 2026
- Addressable patients annually us
- 65000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.